Aerie Pharmaceuticals ( ) - 株価, ニュースと分析DB:0P0

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

0P0 株式概要

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States.

会社概要

0P0 ファンダメンタル分析
スノーフレーク・スコア
評価	4/6
将来の成長	4/6
過去の実績	0/6
財務の健全性	2/6
配当金	0/6

報酬

Trading at 87.8% below our estimate of its fair value

Earnings are forecast to grow 67.47% per year

Earnings have grown 13.7% per year over the past 5 years

リスク分析

Negative shareholders equity

Highly volatile share price over the past 3 months

Shareholders have been diluted in the past year

Aerie Pharmaceuticals, Inc. 競合他社

PharmaSGP Holding

XTRA:PSG

€278.2m

Dermapharm Holding

XTRA:DMP

€1.9b

MPH Health Care

DB:93M1

€114.7m

SynBiotic

DUSE:SBX

€37.7m

価格と性能

の歴代最高値、変動、値下がりまとめAerie Pharmaceuticals
過去の株価
現在の株価	US$14.50
52週高値	US$15.70
52週安値	US$4.58
ベータ	-0.062
11ヶ月の変化	-5.23%
3ヶ月変化	33.03%
1年変化	63.84%
33年間の変化	-14.71%
5年間の変化	-71.88%
IPOからの変化	16.98%

Recent updates

株主還元

	0P0	DE Pharmaceuticals	DE 市場
7D	0%	-5.6%	-0.1%
1Y	63.8%	-18.5%	2.3%

業界別リターン: 0P0 exceeded the German Pharmaceuticals industry which returned -10.8% over the past year.

リターン対市場: 0P0 exceeded the German Market which returned -21.6% over the past year.

価格変動

Is 0P0's price volatile compared to industry and market?
0P0 volatility
0P0 Average Weekly Movement	10.9%
Pharmaceuticals Industry Average Movement	5.7%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.3%
10% least volatile stocks in DE Market	2.5%

安定した株価: 0P0's share price has been volatile over the past 3 months.

時間の経過による変動: 0P0's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
2005	376	Raj Kannan	www.aeriepharma.com

Aerie Pharmaceuticals, Inc. 基礎のまとめ

Aerie Pharmaceuticals の収益と売上を時価総額と比較するとどうか。
0P0 基礎統計学
時価総額	€735.53m
収益（TTM）	-€35.68m
売上高(TTM)	€208.81m

3.5x

P/Sレシオ

-20.6x

PER（株価収益率

0P0 は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
0P0 損益計算書（TTM）
収益	US$213.94m
売上原価	US$23.52m
売上総利益	US$190.42m
その他の費用	US$226.98m
収益	-US$36.55m

直近の収益報告

Sep 30, 2022

次回決算日

該当なし

一株当たり利益（EPS）	-0.74
グロス・マージン	89.01%
純利益率	-17.09%
有利子負債／自己資本比率	-190.6%

0P0 の長期的なパフォーマンスは？

過去の実績と比較を見る

This company is no longer active

0P0 株式概要

報酬

リスク分析

Aerie Pharmaceuticals, Inc. 競合他社

XTRA:PSG

€278.2m

XTRA:DMP

€1.9b

DB:93M1

€114.7m

DUSE:SBX

€37.7m

価格と性能

最新ニュース

Aerie Pharmaceuticals, Inc.(NasdaqGM:AERI) dropped from NASDAQ Composite Index

Aerie Pharmaceuticals, Inc. Announces Management Changes

Third quarter 2022 earnings released: US$0.56 loss per share (vs US$0.86 loss in 3Q 2021)

Alcon Inc. (SWX:ALC) entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI) for approximately $770 million.

Second quarter 2022 earnings released: US$0.41 loss per share (vs US$0.84 loss in 2Q 2021)

Aerie Pharmaceuticals, Inc. Announces First Participant Dosed in the Comet-3 Study of Ar-15512 for the Treatment of Dry Eye Disease

Recent updates

Aerie Pharmaceuticals, Inc.(NasdaqGM:AERI) dropped from NASDAQ Composite Index

Aerie Pharmaceuticals, Inc. Announces Management Changes

Third quarter 2022 earnings released: US$0.56 loss per share (vs US$0.86 loss in 3Q 2021)

Alcon Inc. (SWX:ALC) entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI) for approximately $770 million.

Second quarter 2022 earnings released: US$0.41 loss per share (vs US$0.84 loss in 2Q 2021)

Aerie Pharmaceuticals, Inc. Announces First Participant Dosed in the Comet-3 Study of Ar-15512 for the Treatment of Dry Eye Disease

Aerie Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease

Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease

First quarter 2022 earnings released: US$0.76 loss per share (vs US$0.91 loss in 1Q 2021)

No longer forecast to breakeven

Dr. Gerald D. Cagle to Not Stand for Re-Election as Director of Aerie Pharmaceuticals, Inc

Aerie Pharmaceuticals, Inc. Announces Retirement of Kathleen McGinley as Chief Human Resources Officer and Vice President, Corporate Services, Effective March 31, 2022

Aerie Pharmaceuticals, Inc. Announces Executive Changes

Aerie Pharmaceuticals, Inc. Announces Executive Changes

No longer forecast to breakeven

Aerie Pharmaceuticals, Inc. Announces Revenue Guidance for the Full Year for 2022

Aerie Pharmaceuticals, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Forecast to breakeven in 2024

Insufficient new directors

Third quarter 2021 earnings released: US$0.86 loss per share (vs US$0.86 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.84 loss per share (vs US$1.05 loss in 2Q 2020)

CFO, Secretary & Treasurer Richard Rubino has left the company

Aerie Pharmaceuticals Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil Ophthalmic Solution in Japan

Forecast to breakeven in 2024

New 90-day high: €16.00

Full year 2020 earnings released: US$3.99 loss per share (vs US$4.39 loss in FY 2019)

Revenue beats expectations

Aerie Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: €11.70

Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%

New 90-day high: €11.60

Aerie Pharmaceuticals, Inc. Receives Positive CHMP Opinion for Roclanda® in the European Union

Third quarter 2020 earnings released: US$0.86 loss per share

Revenue beats expectations

Aerie Pharmaceuticals, Inc. Announces Commencement of Comet-1

Aerie Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: €8.15

Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-15512 (TRPM8 Agonist) Eye Drop for Dry Eye Disease

Aerie Pharmaceuticals, Inc. Announces Successful Interim 90-Day Topline Data from Its Six-Month Phase 3B Clinical Trial in Europe Known as Mercury 3

New 90-day low - €8.85

New 90-day low - €9.55

First half earnings released

New 90-day low - €10.00

株主還元

価格変動

会社概要

Aerie Pharmaceuticals, Inc. 基礎のまとめ

3.5x

-20.6x

収益と収入